BioSpace News Archive

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023.

Alkermes plc filed its definitive proxy statement with the U.S. Securities and Exchange Commission and issued a letter to its shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

Structure Therapeutics Inc. announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus who are overweight or obese.

Takeda and HUTCHMED Limited announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.

Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology Annual Meeting, taking place from June 2-6, 2023.

Evaxion Biotech A/S to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma on June 3, at the 2023 ASCO annual meeting, in Chicago, Illinois.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of three abstracts on the American Society of Clinical Oncology website.

PDS Biotechnology Corporation announced promising interim data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer.

Replimune Group, Inc. announced multiple presentations at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL from June 2-6, 2023.